drugset
drugset / Trial / NCT03017495

A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam

NCT03017495 ↗

Phase 1 Completed 20 enrolled Idorsia Pharmaceuticals Ltd.
NaSingle-groupOpen-labelOther

Summary

The main objectives of this phase 1 trial are to evaluate the effect of food on the pharmacokinetics (i.e. how long and how much a compound is present in the blood) of ACT-541468 and to evaluate whether ACT-541468 can affect the pharmacokinetics of midazolam, a CYP3A4 substrate.

Timeline

Start
2017-01-01
Primary completion
2017-02-01
Completion
2017-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 25 mg Oral
Subject Midazolam Small molecule — Oral

Indications

No indication recorded.